{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T05:59:16Z","timestamp":1793771956611,"version":"4.6.1"},"reference-count":182,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82271234"],"award-info":[{"award-number":["82271234"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82060219"],"award-info":[{"award-number":["82060219"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20212ACB216009"],"award-info":[{"award-number":["20212ACB216009"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20212BAB216048"],"award-info":[{"award-number":["20212BAB216048"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20202BBGL7305 8"],"award-info":[{"award-number":["20202BBGL7305 8"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20202BBGL73105"],"award-info":[{"award-number":["20202BBGL73105"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06105-1","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T04:45:02Z","timestamp":1737434702000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["From diagnosis to treatment: exploring the mechanisms underlying optic neuritis in multiple sclerosis"],"prefix":"10.1186","volume":"23","author":[{"given":"Bin","family":"Tong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maolin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6718-6490","authenticated-orcid":false,"given":"Fuzhou","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"6105_CR1","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1002\/ana.24497","volume":"78","author":"JM Frischer","year":"2015","unstructured":"Frischer JM, Weigand SD, Guo Y, Kale N, Parisi JE, Pirko I, Mandrekar J, Bramow S, Metz I, Br\u00fcck W, et al. Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque. Ann Neurol. 2015;78:710\u201321.","journal-title":"Ann Neurol"},{"key":"6105_CR2","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1001\/jamaneurol.2023.1135","volume":"80","author":"M Hittle","year":"2023","unstructured":"Hittle M, Culpepper WJ, Langer-Gould A, Marrie RA, Cutter GR, Kaye WE, Wagner L, Topol B, LaRocca NG, Nelson LM, Wallin MT. Population-based estimates for the prevalence of multiple sclerosis in the united states by race, ethnicity, age, sex, and geographic region. JAMA Neurol. 2023;80:693\u2013701.","journal-title":"JAMA Neurol"},{"key":"6105_CR3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1093\/brain\/awaa361","volume":"144","author":"A Petzold","year":"2021","unstructured":"Petzold A, Chua SYL, Khawaja AP, Keane PA, Khaw PT, Reisman C, Dhillon B, Strouthidis NG, Foster PJ, Patel PJ. Retinal asymmetry in multiple sclerosis. Brain. 2021;144:224\u201335.","journal-title":"Brain"},{"key":"6105_CR4","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1093\/cei\/uxac063","volume":"209","author":"L Fern\u00e1ndez Blanco","year":"2022","unstructured":"Fern\u00e1ndez Blanco L, Marzin M, Leistra A, van der Valk P, Nutma E, Amor S. Immunopathology of the optic nerve in multiple sclerosis. Clin Exp Immunol. 2022;209:236\u201346.","journal-title":"Clin Exp Immunol"},{"key":"6105_CR5","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1177\/1352458513479840","volume":"19","author":"L Jasse","year":"2013","unstructured":"Jasse L, Vukusic S, Durand-Dubief F, Vartin C, Piras C, Bernard M, P\u00e9lisson D, Confavreux C, Vighetto A, Tilikete C. Persistent visual impairment in multiple sclerosis: prevalence, mechanisms and resulting disability. Mult Scler. 2013;19:1618\u201326.","journal-title":"Mult Scler"},{"key":"6105_CR6","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1177\/1352458517690822","volume":"23","author":"LJ Balcer","year":"2017","unstructured":"Balcer LJ, Raynowska J, Nolan R, Galetta SL, Kapoor R, Benedict R, Phillips G, LaRocca N, Hudson L, Rudick R. Validity of low-contrast letter acuity as a visual performance outcome measure for multiple sclerosis. Mult Scler. 2017;23:734\u201347.","journal-title":"Mult Scler"},{"key":"6105_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ana.24030","volume":"75","author":"I Gabilondo","year":"2014","unstructured":"Gabilondo I, Mart\u00ednez-Lapiscina EH, Mart\u00ednez-Heras E, Fraga-Pumar E, Llufriu S, Ortiz S, Bullich S, Sepulveda M, Falcon C, Berenguer J, et al. Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. Ann Neurol. 2014;75:98\u2013107.","journal-title":"Ann Neurol"},{"key":"6105_CR8","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1007\/s00415-021-10437-5","volume":"268","author":"D Jakimovski","year":"2021","unstructured":"Jakimovski D, Benedict RHB, Weinstock-Guttman B, Ozel O, Fuchs TA, Lincoff N, Bergsland N, Dwyer MG, Zivadinov R. Visual deficits and cognitive assessment of multiple sclerosis: confounder, correlate, or both? J Neurol. 2021;268:2578\u201388.","journal-title":"J Neurol"},{"key":"6105_CR9","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1212\/01.wnl.0000259521.14704.a8","volume":"68","author":"LJ Balcer","year":"2007","unstructured":"Balcer LJ, Galetta SL, Calabresi PA, Confavreux C, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Miller DH, et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology. 2007;68:1299\u2013304.","journal-title":"Neurology"},{"key":"6105_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fpain.2022.865032","volume":"3","author":"X Yang","year":"2022","unstructured":"Yang X, Li X, Lai M, Wang J, Tan S, Chan HH. Pain symptoms in optic neuritis. Front Pain Res (Lausanne). 2022;3: 865032.","journal-title":"Front Pain Res (Lausanne)"},{"key":"6105_CR11","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.221512","volume":"307","author":"MA Rocca","year":"2023","unstructured":"Rocca MA, Margoni M, Battaglini M, Eshaghi A, Iliff J, Pagani E, Preziosa P, Storelli L, Taoka T, Valsasina P, Filippi M. Emerging perspectives on MRI application in multiple sclerosis: moving from pathophysiology to clinical practice. Radiology. 2023;307: e221512.","journal-title":"Radiology"},{"key":"6105_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0235615","volume":"15","author":"E Caverzasi","year":"2020","unstructured":"Caverzasi E, Cordano C, Zhu AH, Zhao C, Bischof A, Kirkish G, Bennett DJ, Devereux M, Baker N, Inman J, et al. Imaging correlates of visual function in multiple sclerosis. PLoS ONE. 2020;15: e0235615.","journal-title":"PLoS ONE"},{"key":"6105_CR13","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1212\/WNL.53.3.448","volume":"53","author":"F Fazekas","year":"1999","unstructured":"Fazekas F, Barkhof F, Filippi M, Grossman RI, Li DK, McDonald WI, McFarland HF, Paty DW, Simon JH, Wolinsky JS, Miller DH. The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology. 1999;53:448\u201356.","journal-title":"Neurology"},{"key":"6105_CR14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/S1474-4422(15)00393-2","volume":"15","author":"M Filippi","year":"2016","unstructured":"Filippi M, Rocca MA, Ciccarelli O, De Stefano N, Evangelou N, Kappos L, Rovira A, Sastre-Garriga J, Tintor\u00e8 M, Frederiksen JL, et al. MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. Lancet Neurol. 2016;15:292\u2013303.","journal-title":"Lancet Neurol"},{"key":"6105_CR15","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.neuron.2006.08.012","volume":"51","author":"S Mori","year":"2006","unstructured":"Mori S, Zhang J. Principles of diffusion tensor imaging and its applications to basic neuroscience research. Neuron. 2006;51:527\u201339.","journal-title":"Neuron"},{"key":"6105_CR16","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1212\/WNL.0000000000000522","volume":"82","author":"A Klistorner","year":"2014","unstructured":"Klistorner A, Sriram P, Vootakuru N, Wang C, Barnett MH, Garrick R, Parratt J, Levin N, Raz N, Van der Walt A, et al. Axonal loss of retinal neurons in multiple sclerosis associated with optic radiation lesions. Neurology. 2014;82:2165\u201372.","journal-title":"Neurology"},{"key":"6105_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/nbm.3888","volume":"32","author":"M Cercignani","year":"2019","unstructured":"Cercignani M, Gandini Wheeler-Kingshott C. From micro- to macro-structures in multiple sclerosis: what is the added value of diffusion imaging. NMR Biomed. 2019;32: e3888.","journal-title":"NMR Biomed"},{"key":"6105_CR18","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1007\/s00415-016-8118-z","volume":"263","author":"I de Kouchkovsky","year":"2016","unstructured":"de Kouchkovsky I, Fieremans E, Fleysher L, Herbert J, Grossman RI, Inglese M. Quantification of normal-appearing white matter tract integrity in multiple sclerosis: a diffusion kurtosis imaging study. J Neurol. 2016;263:1146\u201355.","journal-title":"J Neurol"},{"key":"6105_CR19","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.nicl.2016.05.014","volume":"11","author":"P Manogaran","year":"2016","unstructured":"Manogaran P, Vavasour IM, Lange AP, Zhao Y, McMullen K, Rauscher A, Carruthers R, Li DK, Traboulsee AL, Kolind SH. Quantifying visual pathway axonal and myelin loss in multiple sclerosis and neuromyelitis optica. NeuroImage Clin. 2016;11:743\u201350.","journal-title":"NeuroImage Clin"},{"key":"6105_CR20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209677","volume":"103","author":"J Sastre-Garriga","year":"2024","unstructured":"Sastre-Garriga J, Vidal-Jordana A, Toosy AT, Enzinger C, Granziera C, Frederiksen J, Ciccarelli O, Filippi M, Montalban X, Tintore M. Value of Optic nerve MRI in multiple sclerosis Clinical Management: a MAGNIMS position paper and future perspectives. Neurology. 2024;103: e209677.","journal-title":"Neurology"},{"key":"6105_CR21","doi-asserted-by":"publisher","first-page":"0780","DOI":"10.5455\/annalsmedres.2019.11.772","volume":"27","author":"A Dogan","year":"2020","unstructured":"Dogan A, Baykara M. The evaluation of the optic nerve in multiple sclerosis using MRI histogram analysis. Ann Med Res. 2020;27:0780\u20133.","journal-title":"Ann Med Res"},{"key":"6105_CR22","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1002\/ana.25471","volume":"85","author":"O Aktas","year":"2019","unstructured":"Aktas O, Hartung H-P. CSI: multiple sclerosis. Tracing optic nerve involvement by standardized optical coherence tomography. Ann Neurol. 2019;85:615\u20137.","journal-title":"Ann Neurol"},{"key":"6105_CR23","doi-asserted-by":"publisher","first-page":"e1130","DOI":"10.1212\/WNL.0000000000006207","volume":"91","author":"WJ Brownlee","year":"2018","unstructured":"Brownlee WJ, Miszkiel KA, Tur C, Barkhof F, Miller DH, Ciccarelli O. Inclusion of optic nerve involvement in dissemination in space criteria for multiple sclerosis. Neurology. 2018;91:e1130\u20134.","journal-title":"Neurology"},{"key":"6105_CR24","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nrneurol.2014.108","volume":"10","author":"A Petzold","year":"2014","unstructured":"Petzold A, Wattjes MP, Costello F, Flores-Rivera J, Fraser CL, Fujihara K, Leavitt J, Marignier R, Paul F, Schippling S, et al. The investigation of acute optic neuritis: a review and proposed protocol. Nat Rev Neurol. 2014;10:447\u201358.","journal-title":"Nat Rev Neurol"},{"key":"6105_CR25","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12974-023-02763-4","volume":"20","author":"S Mohammadi","year":"2023","unstructured":"Mohammadi S, Gouravani M, Salehi MA, Arevalo JF, Galetta SL, Harandi H, Frohman EM, Frohman TC, Saidha S, Sattarnezhad N, Paul F. Optical coherence tomography angiography measurements in multiple sclerosis: a systematic review and meta-analysis. J Neuroinflamm. 2023;20:85.","journal-title":"J Neuroinflamm"},{"key":"6105_CR26","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1177\/1352458519872751","volume":"26","author":"J Lambe","year":"2020","unstructured":"Lambe J, Saidha S, Bermel RA. Optical coherence tomography and multiple sclerosis: Update on clinical application and role in clinical trials. Mult Scler. 2020;26:624\u201339.","journal-title":"Mult Scler"},{"key":"6105_CR27","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/S1474-4422(10)70168-X","volume":"9","author":"A Petzold","year":"2010","unstructured":"Petzold A, de Boer JF, Schippling S, Vermersch P, Kardon R, Green A, Calabresi PA, Polman C. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 2010;9:921\u201332.","journal-title":"Lancet Neurol"},{"key":"6105_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2302","volume":"11","author":"A Mehmood","year":"2021","unstructured":"Mehmood A, Ali W, Song S, Din ZU, Guo RY, Shah W, Ilahi I, Yin B, Yan H, Zhang L, et al. Optical coherence tomography monitoring and diagnosing retinal changes in multiple sclerosis. Brain Behav. 2021;11: e2302.","journal-title":"Brain Behav"},{"key":"6105_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.preteyeres.2017.11.003","volume":"64","author":"RF Spaide","year":"2018","unstructured":"Spaide RF, Fujimoto JG, Waheed NK, Sadda SR, Staurenghi G. Optical coherence tomography angiography. Prog Retin Eye Res. 2018;64:1\u201355.","journal-title":"Prog Retin Eye Res"},{"key":"6105_CR30","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1042\/CS20170981","volume":"131","author":"S Martinez Sosa","year":"2017","unstructured":"Martinez Sosa S, Smith KJ. Understanding a role for hypoxia in lesion formation and location in the deep and periventricular white matter in small vessel disease and multiple sclerosis. Clin Sci (Lond). 2017;131:2503\u201324.","journal-title":"Clin Sci (Lond)"},{"key":"6105_CR31","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1093\/brain\/awaa049","volume":"143","author":"I Kleerekooper","year":"2020","unstructured":"Kleerekooper I, Petzold A, Trip SA. Anterior visual system imaging to investigate energy failure in multiple sclerosis. Brain. 2020;143:1999\u20132008.","journal-title":"Brain"},{"key":"6105_CR32","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","volume":"20","author":"R Marignier","year":"2021","unstructured":"Marignier R, Hacohen Y, Cobo-Calvo A, Pr\u00f6bstel AK, Aktas O, Alexopoulos H, Amato MP, Asgari N, Banwell B, Bennett J, et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol. 2021;20:762\u201372.","journal-title":"Lancet Neurol"},{"key":"6105_CR33","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001135","volume":"9","author":"M Denis","year":"2022","unstructured":"Denis M, Woillez JP, Smirnov VM, Drumez E, Lannoy J, Boucher J, Zedet M, Pruvo JP, Labreuche J, Zephir H, et al. Optic nerve lesion length at the acute phase of optic neuritis is predictive of retinal neuronal loss. Neurol Neuroimmunol Neuroinflamm. 2022;9: e1135.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"6105_CR34","doi-asserted-by":"publisher","first-page":"13890","DOI":"10.1038\/s41598-020-70919-w","volume":"10","author":"T Akaishi","year":"2020","unstructured":"Akaishi T, Takahashi T, Misu T, Abe M, Ishii T, Fujimori J, Aoki M, Fujihara K, Nakashima I. Progressive patterns of neurological disability in multiple sclerosis and neuromyelitis optica spectrum disorders. Sci Rep. 2020;10:13890.","journal-title":"Sci Rep"},{"key":"6105_CR35","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001126","volume":"9","author":"JS Graves","year":"2022","unstructured":"Graves JS, Oertel FC, Van der Walt A, Collorone S, Sotirchos ES, Pihl-Jensen G, Albrecht P, Yeh EA, Saidha S, Frederiksen J, et al. Leveraging visual outcome measures to advance therapy development in neuroimmunologic disorders. Neurol Neuroimmunol Neuroinflamm. 2022;9: e1126.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"6105_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2125","volume":"11","author":"C Liu","year":"2021","unstructured":"Liu C, Xiao H, Zhang X, Zhao Y, Li R, Zhong X, Wang Y, Shu Y, Chang Y, Wang J, et al. Optical coherence tomography angiography helps distinguish multiple sclerosis from AQP4-IgG-seropositive neuromyelitis optica spectrum disorder. Brain Behav. 2021;11: e02125.","journal-title":"Brain Behav"},{"key":"6105_CR37","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s12974-016-0720-6","volume":"13","author":"F Pache","year":"2016","unstructured":"Pache F, Zimmermann H, Mikolajczak J, Schumacher S, Lacheta A, Oertel FC, Bellmann-Strobl J, Jarius S, Wildemann B, Reindl M, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflamm. 2016;13:282.","journal-title":"J Neuroinflamm"},{"key":"6105_CR38","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s12886-020-01620-9","volume":"20","author":"LJ Rohowetz","year":"2020","unstructured":"Rohowetz LJ, Vu Q, Ablabutyan L, Gratton SM, Kunjukunju N, Wallace BS, Koulen P. Microperimetry as a diagnostic tool for the detection of early, subclinical retinal damage and visual impairment in multiple sclerosis. BMC Ophthalmol. 2020;20:367.","journal-title":"BMC Ophthalmol"},{"key":"6105_CR39","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s00417-020-04948-6","volume":"259","author":"A Gil-Casas","year":"2021","unstructured":"Gil-Casas A, Pi\u00f1ero Llorens DP, Molina-Martin A. Ocular fixation and macular integrity by microperimetry in multiple sclerosis. Graefes Arch Clin Exp Ophthalmol. 2021;259:157\u201364.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"6105_CR40","doi-asserted-by":"publisher","first-page":"27074","DOI":"10.1073\/pnas.1906358116","volume":"116","author":"M Heidari","year":"2019","unstructured":"Heidari M, Radcliff AB, McLellan GJ, Ver Hoeve JN, Chan K, Kiland JA, Keuler NS, August BK, Sebo D, Field AS, Duncan ID. Evoked potentials as a biomarker of remyelination. Proc Natl Acad Sci U S A. 2019;116:27074\u201383.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6105_CR41","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1474-4422(17)30469-6","volume":"17","author":"M Filippi","year":"2018","unstructured":"Filippi M, Preziosa P, Meani A, Ciccarelli O, Mesaros S, Rovira A, Frederiksen J, Enzinger C, Barkhof F, Gasperini C, et al. Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. Lancet Neurol. 2018;17:133\u201342.","journal-title":"Lancet Neurol"},{"key":"6105_CR42","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/B978-0-444-64032-1.00034-5","volume":"160","author":"DJ Creel","year":"2019","unstructured":"Creel DJ. Visually evoked potentials. Handb Clin Neurol. 2019;160:501\u201322.","journal-title":"Handb Clin Neurol"},{"key":"6105_CR43","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/WNO.0000000000000704","volume":"38","author":"L Leocani","year":"2018","unstructured":"Leocani L, Guerrieri S, Comi G. Visual evoked potentials as a biomarker in multiple sclerosis and associated optic neuritis. J Neuroophthalmol. 2018;38:350\u20137.","journal-title":"J Neuroophthalmol"},{"key":"6105_CR44","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1167\/iovs.03-1213","volume":"46","author":"D Sisto","year":"2005","unstructured":"Sisto D, Trojano M, Vetrugno M, Trabucco T, Iliceto G, Sborgia C. Subclinical visual involvement in multiple sclerosis: a study by MRI, VEPs, frequency-doubling perimetry, standard perimetry, and contrast sensitivity. Invest Ophthalmol Vis Sci. 2005;46:1264\u20138.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6105_CR45","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/WNO.0000000000000894","volume":"41","author":"H Jiang","year":"2021","unstructured":"Jiang H, Gameiro GR, Hu H, Monsalve PF, Dong C, Hernandez J, Delgado SR, Porciatti VD, Wang J. Shortened pattern electroretinogram latency and impaired autoregulatory dynamics to steady-state stimuli in patients with multiple sclerosis. J Neuroophthalmol. 2021;41:60\u20138.","journal-title":"J Neuroophthalmol"},{"key":"6105_CR46","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/WNO.0b013e3182745600","volume":"32","author":"V Porciatti","year":"2012","unstructured":"Porciatti V, Ventura LM. Retinal ganglion cell functional plasticity and optic neuropathy: a comprehensive model. J Neuroophthalmol. 2012;32:354\u20138.","journal-title":"J Neuroophthalmol"},{"key":"6105_CR47","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s10633-011-9294-x","volume":"123","author":"CL Fraser","year":"2011","unstructured":"Fraser CL, Holder GE. Electroretinogram findings in unilateral optic neuritis. Doc Ophthalmol. 2011;123:173\u20138.","journal-title":"Doc Ophthalmol"},{"key":"6105_CR48","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1016\/j.clinph.2018.06.012","volume":"129","author":"P Monsalve","year":"2018","unstructured":"Monsalve P, Ren S, Jiang H, Wang J, Kostic M, Gordon P, Porciatti V. Retinal ganglion cell function in recovered optic neuritis: faster is not better. Clin Neurophysiol. 2018;129:1813\u20138.","journal-title":"Clin Neurophysiol"},{"key":"6105_CR49","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1001\/jama.2022.14236","volume":"328","author":"R Marcus","year":"2022","unstructured":"Marcus R. What is multiple sclerosis? JAMA. 2022;328:2078.","journal-title":"JAMA"},{"key":"6105_CR50","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","volume":"20","author":"MP Wattjes","year":"2021","unstructured":"Wattjes MP, Ciccarelli O, Reich DS, Banwell B, de Stefano N, Enzinger C, Fazekas F, Filippi M, Frederiksen J, Gasperini C, et al. 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. Lancet Neurol. 2021;20:653\u201370.","journal-title":"Lancet Neurol"},{"key":"6105_CR51","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S1474-4422(21)00203-9","volume":"20","author":"JI Kira","year":"2021","unstructured":"Kira JI. Redefining use of MRI for patients with multiple sclerosis. Lancet Neurol. 2021;20:591\u20132.","journal-title":"Lancet Neurol"},{"key":"6105_CR52","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41467-019-14118-w","volume":"11","author":"D Schafflick","year":"2020","unstructured":"Schafflick D, Xu CA, Hartlehnert M, Cole M, Schulte-Mecklenbeck A, Lautwein T, Wolbert J, Heming M, Meuth SG, Kuhlmann T, et al. Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. Nat Commun. 2020;11:247.","journal-title":"Nat Commun"},{"key":"6105_CR53","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/ana.410410315","volume":"41","author":"LD Jacobs","year":"1997","unstructured":"Jacobs LD, Kaba SE, Miller CM, Priore RL, Brownscheidle CM. Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis. Ann Neurol. 1997;41:392\u20138.","journal-title":"Ann Neurol"},{"key":"6105_CR54","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1755-3768.1975.tb01143.x","volume":"53","author":"E Nikoskelainen","year":"1975","unstructured":"Nikoskelainen E, Irjala K, Salmi TT. Cerebrospinal fluid findings in patients with optic neuritis. Acta Ophthalmol (Copenh). 1975;53:105\u201319.","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"6105_CR55","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s00415-005-0655-9","volume":"252","author":"P Nilsson","year":"2005","unstructured":"Nilsson P, Larsson E-M, Maly-Sundgren P, Perfekt R, Sandberg-Wollheim M. Predicting the outcome of optic neuritis: evaluation of risk factors after 30 years of follow\u2013up. J Neurol. 2005;252:396\u2013402.","journal-title":"J Neurol"},{"key":"6105_CR56","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12974-019-1440-5","volume":"16","author":"MN Olesen","year":"2019","unstructured":"Olesen MN, Soelberg K, Debrabant B, Nilsson AC, Lillevang ST, Grauslund J, Brandslund I, Madsen JS, Paul F, Smith TJ, et al. Cerebrospinal fluid biomarkers for predicting development of multiple sclerosis in acute optic neuritis: a population-based prospective cohort study. J Neuroinflamm. 2019;16:59.","journal-title":"J Neuroinflamm"},{"key":"6105_CR57","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1136\/bmj.4.5944.567","volume":"4","author":"J Mertin","year":"1974","unstructured":"Mertin J, Hughes D, Caspary EA, Thomson AM, Foster JB, Stewart-Wynne EG. Non-specificity of laboratory test for diagnosis of multiple sclerosis. Br Med J. 1974;4:567\u20139.","journal-title":"Br Med J"},{"key":"6105_CR58","doi-asserted-by":"publisher","first-page":"104","DOI":"10.5603\/AHP.a2022.0014","volume":"53","author":"A Kubiak","year":"2022","unstructured":"Kubiak A, Zi\u00f3\u0142kowska E, Korycka-Wo\u0142owiec A. The diagnostic pitfalls and challenges associated with basic hematological tests. Acta Haematol Pol. 2022;53:104\u201311.","journal-title":"Acta Haematol Pol"},{"key":"6105_CR59","volume":"14","author":"R Talanki Manjunatha","year":"2022","unstructured":"Talanki Manjunatha R, Habib S, Sangaraju SL, Yepez D, Grandes XA. Multiple sclerosis: therapeutic strategies on the horizon. Cureus. 2022;14: e24895.","journal-title":"Cureus"},{"key":"6105_CR60","doi-asserted-by":"publisher","first-page":"e1916","DOI":"10.1212\/WNL.0000000000201027","volume":"99","author":"M Mainguy","year":"2022","unstructured":"Mainguy M, Tillaut H, Degremont A, Le Page E, Mainguy C, Duros S, Polard E, Leray E. Assessing the risk of relapse requiring corticosteroids after in vitro fertilization in women with multiple sclerosis. Neurology. 2022;99:e1916\u201325.","journal-title":"Neurology"},{"key":"6105_CR61","volume-title":"Multiple sclerosis and demyelinating diseases","author":"MS Freedman","year":"2006","unstructured":"Freedman MS. Multiple sclerosis and demyelinating diseases. Lippincott Williams & Wilkins; 2006."},{"key":"6105_CR62","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1001\/jamaneurol.2021.0627","volume":"78","author":"A Patel","year":"2021","unstructured":"Patel A, Sul J, Gordon ML, Steinklein J, Sanguinetti S, Pramanik B, Purohit D, Haroutunian V, Williamson A, Koralnik I, Harel A. Progressive multifocal leukoencephalopathy in a patient with progressive multiple sclerosis treated with ocrelizumab monotherapy. JAMA Neurol. 2021;78:736\u201340.","journal-title":"JAMA Neurol"},{"key":"6105_CR63","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00415-020-10362-z","volume":"269","author":"CG Chisari","year":"2022","unstructured":"Chisari CG, Sgarlata E, Arena S, Toscano S, Luca M, Patti F. Rituximab for the treatment of multiple sclerosis: a review. J Neurol. 2022;269:159\u201383.","journal-title":"J Neurol"},{"key":"6105_CR64","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.autrev.2019.03.011","volume":"18","author":"Y Hu","year":"2019","unstructured":"Hu Y, Nie H, Yu HH, Qin C, Wu LJ, Tang ZP, Tian DS. Efficacy and safety of rituximab for relapsing-remitting multiple sclerosis: a systematic review and meta-analysis. Autoimmun Rev. 2019;18:542\u20138.","journal-title":"Autoimmun Rev"},{"key":"6105_CR65","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1212\/WNL.0000000000002832","volume":"87","author":"P de Flon","year":"2016","unstructured":"de Flon P, Gunnarsson M, Laurell K, S\u00f6derstr\u00f6m L, Birgander R, Lindqvist T, Krauss W, Dring A, Bergman J, Sundstr\u00f6m P, Svenningsson A. Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab. Neurology. 2016;87:141\u20137.","journal-title":"Neurology"},{"key":"6105_CR66","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S1474-4422(19)30151-6","volume":"18","author":"D Ontaneda","year":"2019","unstructured":"Ontaneda D, Tallantyre E, Kalincik T, Planchon SM, Evangelou N. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurol. 2019;18:973\u201380.","journal-title":"Lancet Neurol"},{"key":"6105_CR67","first-page":"80","volume":"29","author":"A Yan","year":"2023","unstructured":"Yan A, Peng K, Chen F. Clinical significance of visual training in improving visual function after retinal detachment in adolescents. Altern Ther Health Med. 2023;29:80\u20134.","journal-title":"Altern Ther Health Med"},{"key":"6105_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2022.101497","volume":"69","author":"A Shah","year":"2022","unstructured":"Shah A, Panchal V, Patel K, Alimohamed Z, Kaka N, Sethi Y, Patel N. Pathogenesis and management of multiple sclerosis revisited. Dis Mon. 2022;69: 101497.","journal-title":"Dis Mon"},{"key":"6105_CR69","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.apmr.2020.08.003","volume":"101","author":"SL Costa","year":"2020","unstructured":"Costa SL, Pandey K, Hrdina J, Rondon M, Devos H. Vision problems in multiple sclerosis. Arch Phys Med Rehabil. 2020;101:2263\u20135.","journal-title":"Arch Phys Med Rehabil"},{"key":"6105_CR70","first-page":"28","volume":"14","author":"J Avasarala","year":"2017","unstructured":"Avasarala J. It\u2019s time for combination therapies: in multiple sclerosis. Innov Clin Neurosci. 2017;14:28\u201330.","journal-title":"Innov Clin Neurosci"},{"key":"6105_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103264","volume":"56","author":"J Correale","year":"2021","unstructured":"Correale J, Halfon MJ, Jack D, Rubstein A, Villa A. Acting centrally or peripherally: a renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis. Mult Scler Relat Disord. 2021;56: 103264.","journal-title":"Mult Scler Relat Disord"},{"key":"6105_CR72","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00401-024-02730-0","volume":"147","author":"A Geladaris","year":"2024","unstructured":"Geladaris A, Torke S, Saberi D, Alankus YB, Streit F, Zechel S, Stadelmann-Nessler C, Fischer A, Boschert U, H\u00e4usler D, Weber MS. BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair. Acta Neuropathol. 2024;147:75.","journal-title":"Acta Neuropathol"},{"key":"6105_CR73","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1016\/S1474-4422(24)00391-0","volume":"23","author":"A van der Walt","year":"2024","unstructured":"van der Walt A. Evobrutinib in multiple sclerosis: challenges and unmet goals. Lancet Neurol. 2024;23:1068\u201370.","journal-title":"Lancet Neurol"},{"key":"6105_CR74","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S1474-4422(21)00237-4","volume":"20","author":"DS Reich","year":"2021","unstructured":"Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallstr\u00f6m E, Zhang X, Mare\u0161 M, et al. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021;20:729\u201338.","journal-title":"Lancet Neurol"},{"key":"6105_CR75","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s12974-024-03267-5","volume":"21","author":"J Langlois","year":"2024","unstructured":"Langlois J, Lange S, Ebeling M, Macnair W, Schmucki R, Li C, DeGeer J, Sudharshan TJJ, Yong VW, Shen YA, et al. Fenebrutinib, a Bruton\u2019s tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways. J Neuroinflamm. 2024;21:276.","journal-title":"J Neuroinflamm"},{"key":"6105_CR76","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jaut.2018.01.001","volume":"87","author":"AM McGinley","year":"2018","unstructured":"McGinley AM, Edwards SC, Raverdeau M, Mills KHG. Th17 cells, \u03b3\u03b4 T cells and their interplay in EAE and multiple sclerosis. J Autoimmun. 2018;87:97\u2013108.","journal-title":"J Autoimmun"},{"key":"6105_CR77","doi-asserted-by":"publisher","first-page":"8217","DOI":"10.3390\/ijms21218217","volume":"21","author":"S Monaco","year":"2020","unstructured":"Monaco S, Nicholas R, Reynolds R, Magliozzi R. Intrathecal inflammation in progressive multiple sclerosis. Int J Mol Sci. 2020;21:8217.","journal-title":"Int J Mol Sci"},{"key":"6105_CR78","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.preteyeres.2018.02.003","volume":"65","author":"M Diedrichs-M\u00f6hring","year":"2018","unstructured":"Diedrichs-M\u00f6hring M, Kaufmann U, Wildner G. The immunopathogenesis of chronic and relapsing autoimmune uveitis\u2014lessons from experimental rat models. Prog Retin Eye Res. 2018;65:107\u201326.","journal-title":"Prog Retin Eye Res"},{"key":"6105_CR79","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00401-018-1809-z","volume":"135","author":"RO Weller","year":"2018","unstructured":"Weller RO, Sharp MM, Christodoulides M, Carare RO, M\u00f8llg\u00e5rd K. The meninges as barriers and facilitators for the movement of fluid, cells and pathogens related to the rodent and human CNS. Acta Neuropathol. 2018;135:363\u201385.","journal-title":"Acta Neuropathol"},{"key":"6105_CR80","doi-asserted-by":"publisher","first-page":"451","DOI":"10.4103\/1673-5374.346462","volume":"18","author":"JL Zhan","year":"2023","unstructured":"Zhan JL, Huang YL, Liang QW, Qu XS, Dong ZM, Du Y, Luo WJ. Anti-inflammatory effect of miR-125a-5p on experimental optic neuritis by promoting the differentiation of Treg cells. Neural Regen Res. 2023;18:451\u20135.","journal-title":"Neural Regen Res"},{"key":"6105_CR81","doi-asserted-by":"publisher","first-page":"325","DOI":"10.2147\/ITT.S255722","volume":"10","author":"M Levy","year":"2021","unstructured":"Levy M, Mealy MA. B-cell targeted treatments for neuromyelitis optica spectrum disorder: a focus on CD19 and CD20. Immunotargets Ther. 2021;10:325\u201331.","journal-title":"Immunotargets Ther"},{"key":"6105_CR82","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41586-024-07130-8","volume":"628","author":"X Yin","year":"2024","unstructured":"Yin X, Zhang S, Lee JH, Dong H, Mourgkos G, Terwilliger G, Kraus A, Geraldo LH, Poulet M, Fischer S, et al. Compartmentalized ocular lymphatic system mediates eye-brain immunity. Nature. 2024;628:204\u201311.","journal-title":"Nature"},{"key":"6105_CR83","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1093\/brain\/awp070","volume":"132","author":"JM Frischer","year":"2009","unstructured":"Frischer JM, Bramow S, Dal-Bianco A, Lucchinetti CF, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Lassmann H. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain. 2009;132:1175\u201389.","journal-title":"Brain"},{"key":"6105_CR84","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1080\/09273948.2022.2079536","volume":"31","author":"S Khalid","year":"2023","unstructured":"Khalid S, Sharma G, Jakati S, Basu S. Mixed B- and T-lymphocyte vitreous infiltrate in multiple sclerosis associated uveitis. Ocul Immunol Inflamm. 2023;31:996\u20138.","journal-title":"Ocul Immunol Inflamm"},{"key":"6105_CR85","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cell.2018.08.011","volume":"175","author":"I Jelcic","year":"2018","unstructured":"Jelcic I, Al Nimer F, Wang J, Lentsch V, Planas R, Jelcic I, Madjovski A, Ruhrmann S, Faigle W, Frauenknecht K, et al. Memory B cells activate brain-homing, autoreactive CD4(+) T cells in multiple sclerosis. Cell. 2018;175:85-100.e123.","journal-title":"Cell"},{"key":"6105_CR86","doi-asserted-by":"publisher","first-page":"25690","DOI":"10.1073\/pnas.2012249117","volume":"117","author":"N Nissimov","year":"2020","unstructured":"Nissimov N, Hajiyeva Z, Torke S, Grondey K, Br\u00fcck W, H\u00e4usser-Kinzel S, Weber MS. B cells reappear less mature and more activated after their anti-CD20-mediated depletion in multiple sclerosis. Proc Natl Acad Sci U S A. 2020;117:25690\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6105_CR87","doi-asserted-by":"publisher","first-page":"1004795","DOI":"10.3389\/fimmu.2023.1004795","volume":"14","author":"J de S\u00e8ze","year":"2023","unstructured":"de S\u00e8ze J, Maillart E, Gueguen A, Laplaud DA, Michel L, Thouvenot E, Zephir H, Zimmer L, Biotti D, Liblau R. Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic. Front Immunol. 2023;14:1004795.","journal-title":"Front Immunol"},{"key":"6105_CR88","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S1474-4422(14)70028-6","volume":"13","author":"L Kappos","year":"2014","unstructured":"Kappos L, Hartung HP, Freedman MS, Boyko A, Rad\u00fc EW, Mikol DD, Lamarine M, Hyvert Y, Freudensprung U, Plitz T, van Beek J. Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol. 2014;13:353\u201363.","journal-title":"Lancet Neurol"},{"key":"6105_CR89","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/ana.21939","volume":"67","author":"A Bar-Or","year":"2010","unstructured":"Bar-Or A, Fawaz L, Fan B, Darlington PJ, Rieger A, Ghorayeb C, Calabresi PA, Waubant E, Hauser SL, Zhang J, Smith CH. Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol. 2010;67:452\u201361.","journal-title":"Ann Neurol"},{"key":"6105_CR90","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1093\/brain\/awac233","volume":"145","author":"P Bhargava","year":"2022","unstructured":"Bhargava P, Hartung HP, Calabresi PA. Contribution of B cells to cortical damage in multiple sclerosis. Brain. 2022;145:3363\u201373.","journal-title":"Brain"},{"key":"6105_CR91","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1177\/1352458516664210","volume":"23","author":"A Mathias","year":"2017","unstructured":"Mathias A, Perriard G, Canales M, Soneson C, Delorenzi M, Schluep M, Du Pasquier RA. Increased ex vivo antigen presentation profile of B cells in multiple sclerosis. Mult Scler. 2017;23:802\u20139.","journal-title":"Mult Scler"},{"key":"6105_CR92","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41419-023-05783-3","volume":"14","author":"W Zhou","year":"2023","unstructured":"Zhou W, Graner M, Paucek P, Beseler C, Boisen M, Bubak A, Asturias F, George W, Graner A, Ormond D, et al. Multiple sclerosis plasma IgG aggregates induce complement-dependent neuronal apoptosis. Cell Death Dis. 2023;14:254.","journal-title":"Cell Death Dis"},{"key":"6105_CR93","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00401-015-1500-6","volume":"130","author":"K Blauth","year":"2015","unstructured":"Blauth K, Soltys J, Matschulat A, Reiter CR, Ritchie A, Baird NL, Bennett JL, Owens GP. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid cause demyelination of spinal cord explants. Acta Neuropathol. 2015;130:765\u201381.","journal-title":"Acta Neuropathol"},{"key":"6105_CR94","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.cell.2018.11.035","volume":"176","author":"OL Rojas","year":"2019","unstructured":"Rojas OL, Pr\u00f6bstel AK, Porfilio EA, Wang AA, Charabati M, Sun T, Lee DSW, Galicia G, Ramaglia V, Ward LA, et al. Recirculating intestinal IgA-producing cells regulate neuroinflammation via IL-10. Cell. 2019;176:610-624.e618.","journal-title":"Cell"},{"key":"6105_CR95","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.jneuroim.2005.05.006","volume":"167","author":"Y Zhang","year":"2005","unstructured":"Zhang Y, Da RR, Hilgenberg LG, Tourtellotte WW, Sobel RA, Smith MA, Olek M, Nagra R, Sudhir G, van den Noort S, Qin Y. Clonal expansion of IgA-positive plasma cells and axon-reactive antibodies in MS lesions. J Neuroimmunol. 2005;167:120\u201330.","journal-title":"J Neuroimmunol"},{"key":"6105_CR96","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3389\/fimmu.2017.00110","volume":"8","author":"Y Chen","year":"2017","unstructured":"Chen Y, Li C, Lu Y, Zhuang H, Gu W, Liu B, Liu F, Sun J, Yan B, Weng D, Chen J. IL-10-producing CD1d(hi)CD5(+) regulatory B cells may play a critical role in modulating immune homeostasis in silicosis patients. Front Immunol. 2017;8:110.","journal-title":"Front Immunol"},{"key":"6105_CR97","doi-asserted-by":"publisher","first-page":"3645","DOI":"10.1172\/JCI46274","volume":"121","author":"Q Ding","year":"2011","unstructured":"Ding Q, Yeung M, Camirand G, Zeng Q, Akiba H, Yagita H, Chalasani G, Sayegh MH, Najafian N, Rothstein DM. Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J Clin Invest. 2011;121:3645\u201356.","journal-title":"J Clin Invest"},{"key":"6105_CR98","doi-asserted-by":"publisher","first-page":"5569","DOI":"10.4049\/jimmunol.1100284","volume":"186","author":"NA Carter","year":"2011","unstructured":"Carter NA, Vasconcellos R, Rosser EC, Tulone C, Mu\u00f1oz-Suano A, Kamanaka M, Ehrenstein MR, Flavell RA, Mauri C. Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1\/Th17 but a decrease in regulatory T cells. J Immunol. 2011;186:5569\u201379.","journal-title":"J Immunol"},{"key":"6105_CR99","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/cmi.2014.56","volume":"12","author":"LH Hsu","year":"2015","unstructured":"Hsu LH, Li KP, Chu KH, Chiang BL. A B-1a cell subset induces Foxp3(-) T cells with regulatory activity through an IL-10-independent pathway. Cell Mol Immunol. 2015;12:354\u201365.","journal-title":"Cell Mol Immunol"},{"key":"6105_CR100","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.jaut.2011.01.005","volume":"36","author":"S Lemoine","year":"2011","unstructured":"Lemoine S, Morva A, Youinou P, Jamin C. Human T cells induce their own regulation through activation of B cells. J Autoimmun. 2011;36:228\u201338.","journal-title":"J Autoimmun"},{"key":"6105_CR101","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1189\/jlb.1008659","volume":"86","author":"KS Kim","year":"2009","unstructured":"Kim KS, Park JY, Jou I, Park SM. Functional implication of BAFF synthesis and release in gangliosides-stimulated microglia. J Leukoc Biol. 2009;86:349\u201359.","journal-title":"J Leukoc Biol"},{"key":"6105_CR102","doi-asserted-by":"publisher","first-page":"6070","DOI":"10.4049\/jimmunol.1400654","volume":"193","author":"MB Mutnal","year":"2014","unstructured":"Mutnal MB, Hu S, Schachtele SJ, Lokensgard JR. Infiltrating regulatory B cells control neuroinflammation following viral brain infection. J Immunol. 2014;193:6070\u201380.","journal-title":"J Immunol"},{"key":"6105_CR103","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.4049\/jimmunol.1900488","volume":"203","author":"MM Hasan","year":"2019","unstructured":"Hasan MM, Thompson-Snipes L, Klintmalm G, Demetris AJ, O\u2019Leary J, Oh S, Joo H. CD24(hi)CD38(hi) and CD24(hi)CD27(+) human regulatory B cells display common and distinct functional characteristics. J Immunol. 2019;203:2110\u201320.","journal-title":"J Immunol"},{"key":"6105_CR104","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1084\/jem.179.3.973","volume":"179","author":"J Zhang","year":"1994","unstructured":"Zhang J, Markovic-Plese S, Lacet B, Raus J, Weiner HL, Hafler DA. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J Exp Med. 1994;179:973\u201384.","journal-title":"J Exp Med"},{"key":"6105_CR105","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/346183a0","volume":"346","author":"K Ota","year":"1990","unstructured":"Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature. 1990;346:183\u20137.","journal-title":"Nature"},{"key":"6105_CR106","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41573-019-0035-2","volume":"18","author":"S Faissner","year":"2019","unstructured":"Faissner S, Plemel JR, Gold R, Yong VW. Progressive multiple sclerosis: from pathophysiology to therapeutic strategies. Nat Rev Drug Discov. 2019;18:905\u201322.","journal-title":"Nat Rev Drug Discov"},{"key":"6105_CR107","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190460","volume":"217","author":"CA Wagner","year":"2020","unstructured":"Wagner CA, Roqu\u00e9 PJ, Goverman JM. Pathogenic T cell cytokines in multiple sclerosis. J Exp Med. 2020;217: e20190460.","journal-title":"J Exp Med"},{"key":"6105_CR108","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nm0502-500","volume":"8","author":"C Lock","year":"2002","unstructured":"Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med. 2002;8:500\u20138.","journal-title":"Nat Med"},{"key":"6105_CR109","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/icb.2017.56","volume":"95","author":"SA Sonar","year":"2017","unstructured":"Sonar SA, Shaikh S, Joshi N, Atre AN, Lal G. IFN-\u03b3 promotes transendothelial migration of CD4(+) T cells across the blood-brain barrier. Immunol Cell Biol. 2017;95:843\u201353.","journal-title":"Immunol Cell Biol"},{"key":"6105_CR110","doi-asserted-by":"publisher","first-page":"4251","DOI":"10.4049\/jimmunol.1303321","volume":"194","author":"X Ding","year":"2015","unstructured":"Ding X, Yan Y, Li X, Li K, Ciric B, Yang J, Zhang Y, Wu S, Xu H, Chen W, et al. Silencing IFN-\u03b3 binding\/signaling in astrocytes versus microglia leads to opposite effects on central nervous system autoimmunity. J Immunol. 2015;194:4251\u201364.","journal-title":"J Immunol"},{"key":"6105_CR111","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/310688a0","volume":"310","author":"GH Wong","year":"1984","unstructured":"Wong GH, Bartlett PF, Clark-Lewis I, Battye F, Schrader JW. Inducible expression of H-2 and Ia antigens on brain cells. Nature. 1984;310:688\u201391.","journal-title":"Nature"},{"key":"6105_CR112","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.bbi.2014.01.001","volume":"37","author":"CK Prajeeth","year":"2014","unstructured":"Prajeeth CK, L\u00f6hr K, Floess S, Zimmermann J, Ulrich R, Gudi V, Beineke A, Baumg\u00e4rtner W, M\u00fcller M, Huehn J, Stangel M. Effector molecules released by Th1 but not Th17 cells drive an M1 response in microglia. Brain Behav Immun. 2014;37:248\u201359.","journal-title":"Brain Behav Immun"},{"key":"6105_CR113","doi-asserted-by":"publisher","first-page":"564","DOI":"10.4049\/jimmunol.1400825","volume":"193","author":"JS Stoolman","year":"2014","unstructured":"Stoolman JS, Duncker PC, Huber AK, Segal BM. Site-specific chemokine expression regulates central nervous system inflammation and determines clinical phenotype in autoimmune encephalomyelitis. J Immunol. 2014;193:564\u201370.","journal-title":"J Immunol"},{"key":"6105_CR114","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1742-2094-9-7","volume":"9","author":"E Lee","year":"2012","unstructured":"Lee E, Chanamara S, Pleasure D, Soulika AM. IFN-gamma signaling in the central nervous system controls the course of experimental autoimmune encephalomyelitis independently of the localization and composition of inflammatory foci. J Neuroinflamm. 2012;9:7.","journal-title":"J Neuroinflamm"},{"key":"6105_CR115","doi-asserted-by":"publisher","first-page":"E5038","DOI":"10.1073\/pnas.1505955112","volume":"112","author":"RA Sosa","year":"2015","unstructured":"Sosa RA, Murphey C, Robinson RR, Forsthuber TG. IFN-\u03b3 ameliorates autoimmune encephalomyelitis by limiting myelin lipid peroxidation. Proc Natl Acad Sci U S A. 2015;112:E5038-5047.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6105_CR116","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1182\/blood-2006-07-034231","volume":"109","author":"L Conti","year":"2007","unstructured":"Conti L, Regis G, Longo A, Bernabei P, Chiarle R, Giovarelli M, Novelli F. In the absence of IGF-1 signaling, IFN-gamma suppresses human malignant T-cell growth. Blood. 2007;109:2496\u2013504.","journal-title":"Blood"},{"key":"6105_CR117","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/ana.21652","volume":"65","author":"L Durelli","year":"2009","unstructured":"Durelli L, Conti L, Clerico M, Boselli D, Contessa G, Ripellino P, Ferrero B, Eid P, Novelli F. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol. 2009;65:499\u2013509.","journal-title":"Ann Neurol"},{"key":"6105_CR118","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/ni.1610","volume":"9","author":"N Manel","year":"2008","unstructured":"Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol. 2008;9:641\u20139.","journal-title":"Nat Immunol"},{"key":"6105_CR119","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature07021","volume":"454","author":"L Yang","year":"2008","unstructured":"Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M, Kuchroo VK, Hafler DA. IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature. 2008;454:350\u20132.","journal-title":"Nature"},{"key":"6105_CR120","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/nm1651","volume":"13","author":"H Kebir","year":"2007","unstructured":"Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, Giuliani F, Arbour N, Becher B, Prat A. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat Med. 2007;13:1173\u20135.","journal-title":"Nat Med"},{"key":"6105_CR121","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.bbrc.2018.11.021","volume":"507","author":"MT Rahman","year":"2018","unstructured":"Rahman MT, Ghosh C, Hossain M, Linfield D, Rezaee F, Janigro D, Marchi N, van Boxel-Dezaire AHH. IFN-\u03b3, IL-17A, or zonulin rapidly increase the permeability of the blood-brain and small intestinal epithelial barriers: relevance for neuro-inflammatory diseases. Biochem Biophys Res Commun. 2018;507:274\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"6105_CR122","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jneuroim.2019.04.011","volume":"332","author":"AF Setiadi","year":"2019","unstructured":"Setiadi AF, Abbas AR, Jeet S, Wong K, Bischof A, Peng I, Lee J, Bremer M, Eggers EL, DeVoss J, et al. IL-17A is associated with the breakdown of the blood-brain barrier in relapsing-remitting multiple sclerosis. J Neuroimmunol. 2019;332:147\u201354.","journal-title":"J Neuroimmunol"},{"key":"6105_CR123","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.4049\/jimmunol.1801683","volume":"203","author":"A Colamatteo","year":"2019","unstructured":"Colamatteo A, Maggioli E, Azevedo Loiola R, Hamid Sheikh M, Cal\u00ec G, Bruzzese D, Maniscalco GT, Centonze D, Buttari F, Lanzillo R, et al. Reduced Annexin A1 expression associates with disease severity and inflammation in multiple sclerosis patients. J Immunol. 2019;203:1753\u201365.","journal-title":"J Immunol"},{"key":"6105_CR124","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3389\/fncel.2018.00352","volume":"12","author":"CK Prajeeth","year":"2018","unstructured":"Prajeeth CK, Dittrich-Breiholz O, Talbot SR, Robert PA, Huehn J, Stangel M. IFN-\u03b3 producing Th1 cells induce different transcriptional profiles in microglia and astrocytes. Front Cell Neurosci. 2018;12:352.","journal-title":"Front Cell Neurosci"},{"key":"6105_CR125","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-2094-6-14","volume":"6","author":"J Das Sarma","year":"2009","unstructured":"Das Sarma J, Ciric B, Marek R, Sadhukhan S, Caruso ML, Shafagh J, Fitzgerald DC, Shindler KS, Rostami A. Functional interleukin-17 receptor A is expressed in central nervous system glia and upregulated in experimental autoimmune encephalomyelitis. J Neuroinflamm. 2009;6:14.","journal-title":"J Neuroinflamm"},{"key":"6105_CR126","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.immuni.2010.03.004","volume":"32","author":"Z Kang","year":"2010","unstructured":"Kang Z, Altuntas CZ, Gulen MF, Liu C, Giltiay N, Qin H, Liu L, Qian W, Ransohoff RM, Bergmann C, et al. Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. Immunity. 2010;32:414\u201325.","journal-title":"Immunity"},{"key":"6105_CR127","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/BF00294613","volume":"80","author":"H Konno","year":"1990","unstructured":"Konno H, Yamamoto T, Suzuki H, Yamamoto H, Iwasaki Y, Ohara Y, Terunuma H, Harata N. Targeting of adoptively transferred experimental allergic encephalitis lesion at the sites of wallerian degeneration. Acta Neuropathol. 1990;80:521\u20136.","journal-title":"Acta Neuropathol"},{"key":"6105_CR128","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s40478-019-0767-6","volume":"7","author":"J Jin","year":"2019","unstructured":"Jin J, Smith MD, Kersbergen CJ, Kam TI, Viswanathan M, Martin K, Dawson TM, Dawson VL, Zack DJ, Whartenby K, Calabresi PA. Glial pathology and retinal neurotoxicity in the anterior visual pathway in experimental autoimmune encephalomyelitis. Acta Neuropathol Commun. 2019;7:125.","journal-title":"Acta Neuropathol Commun"},{"key":"6105_CR129","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/glia.24148","volume":"70","author":"MK Sen","year":"2022","unstructured":"Sen MK, Mahns DA, Coorssen JR, Shortland PJ. The roles of microglia and astrocytes in phagocytosis and myelination: insights from the cuprizone model of multiple sclerosis. Glia. 2022;70:1215\u201350.","journal-title":"Glia"},{"key":"6105_CR130","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/ni1372","volume":"7","author":"G van Loo","year":"2006","unstructured":"van Loo G, De Lorenzi R, Schmidt H, Huth M, Mildner A, Schmidt-Supprian M, Lassmann H, Prinz MR, Pasparakis M. Inhibition of transcription factor NF-kappaB in the central nervous system ameliorates autoimmune encephalomyelitis in mice. Nat Immunol. 2006;7:954\u201361.","journal-title":"Nat Immunol"},{"key":"6105_CR131","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809665","volume":"11","author":"N Reichenbach","year":"2019","unstructured":"Reichenbach N, Delekate A, Plescher M, Schmitt F, Krauss S, Blank N, Halle A, Petzold GC. Inhibition of Stat3-mediated astrogliosis ameliorates pathology in an Alzheimer\u2019s disease model. EMBO Mol Med. 2019;11: e9665.","journal-title":"EMBO Mol Med"},{"key":"6105_CR132","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2021.105107","volume":"148","author":"X Zhao","year":"2021","unstructured":"Zhao X, Liu S, Yang X, Liu Y, Liu G, Fan K, Ma J. Cathepsin C aggravates neuroinflammation via promoting production of CCL2 and CXCL2 in glial cells and neurons in a cryogenic brain lesion. Neurochem Int. 2021;148: 105107.","journal-title":"Neurochem Int"},{"key":"6105_CR133","doi-asserted-by":"publisher","first-page":"8175","DOI":"10.1523\/JNEUROSCI.1137-14.2014","volume":"34","author":"M Moreno","year":"2014","unstructured":"Moreno M, Bannerman P, Ma J, Guo F, Miers L, Soulika AM, Pleasure D. Conditional ablation of astroglial CCL2 suppresses CNS accumulation of M1 macrophages and preserves axons in mice with MOG peptide EAE. J Neurosci. 2014;34:8175\u201385.","journal-title":"J Neurosci"},{"key":"6105_CR134","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/1742-2094-11-105","volume":"11","author":"E Mills Ko","year":"2014","unstructured":"Mills Ko E, Ma JH, Guo F, Miers L, Lee E, Bannerman P, Burns T, Ko D, Sohn J, Soulika AM, Pleasure D. Deletion of astroglial CXCL10 delays clinical onset but does not affect progressive axon loss in a murine autoimmune multiple sclerosis model. J Neuroinflamm. 2014;11:105.","journal-title":"J Neuroinflamm"},{"key":"6105_CR135","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/s41593-018-0212-3","volume":"21","author":"G Locatelli","year":"2018","unstructured":"Locatelli G, Theodorou D, Kendirli A, Jord\u00e3o MJC, Staszewski O, Phulphagar K, Cantuti-Castelvetri L, Dagkalis A, Bessis A, Simons M, et al. Mononuclear phagocytes locally specify and adapt their phenotype in a multiple sclerosis model. Nat Neurosci. 2018;21:1196\u2013208.","journal-title":"Nat Neurosci"},{"key":"6105_CR136","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s00401-021-02366-4","volume":"142","author":"M Gharagozloo","year":"2021","unstructured":"Gharagozloo M, Smith MD, Jin J, Garton T, Taylor M, Chao A, Meyers K, Kornberg MD, Zack DJ, Ohayon J, et al. Complement component 3 from astrocytes mediates retinal ganglion cell loss during neuroinflammation. Acta Neuropathol. 2021;142:899\u2013915.","journal-title":"Acta Neuropathol"},{"key":"6105_CR137","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41586-020-03116-4","volume":"590","author":"LM Sanmarco","year":"2021","unstructured":"Sanmarco LM, Wheeler MA, Guti\u00e9rrez-V\u00e1zquez C, Polonio CM, Linnerbauer M, Pinho-Ribeiro FA, Li Z, Giovannoni F, Batterman KV, Scalisi G, et al. Gut-licensed IFN\u03b3(+) NK cells drive LAMP1(+)TRAIL(+) anti-inflammatory astrocytes. Nature. 2021;590:473\u20139.","journal-title":"Nature"},{"key":"6105_CR138","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.molmed.2019.11.006","volume":"26","author":"JD Laman","year":"2020","unstructured":"Laman JD, Hart BA, Power C, Dziarski R. Bacterial peptidoglycan as a driver of chronic brain inflammation. Trends Mol Med. 2020;26:670\u201382.","journal-title":"Trends Mol Med"},{"key":"6105_CR139","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.bbi.2023.04.008","volume":"111","author":"BD Hobson","year":"2023","unstructured":"Hobson BD, Stanley AT, De Los Santos MB, Culbertson B, Mosharov EV, Sims PA, Sulzer D. Conserved and cell type-specific transcriptional responses to IFN-\u03b3 in the ventral midbrain. Brain Behav Immun. 2023;111:277\u201391.","journal-title":"Brain Behav Immun"},{"key":"6105_CR140","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00401-003-0766-2","volume":"106","author":"K Imamura","year":"2003","unstructured":"Imamura K, Hishikawa N, Sawada M, Nagatsu T, Yoshida M, Hashizume Y. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson\u2019s disease brains. Acta Neuropathol. 2003;106:518\u201326.","journal-title":"Acta Neuropathol"},{"key":"6105_CR141","doi-asserted-by":"publisher","first-page":"eabh0609","DOI":"10.1126\/sciadv.abh0609","volume":"7","author":"Z Jie","year":"2021","unstructured":"Jie Z, Ko CJ, Wang H, Xie X, Li Y, Gu M, Zhu L, Yang JY, Gao T, Ru W, et al. Microglia promote autoimmune inflammation via the noncanonical NF-\u03baB pathway. Sci Adv. 2021;7:eabh0609.","journal-title":"Sci Adv"},{"key":"6105_CR142","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.redox.2017.09.017","volume":"14","author":"L Hou","year":"2018","unstructured":"Hou L, Wang K, Zhang C, Sun F, Che Y, Zhao X, Zhang D, Li H, Wang Q. Complement receptor 3 mediates NADPH oxidase activation and dopaminergic neurodegeneration through a Src-Erk-dependent pathway. Redox Biol. 2018;14:250\u201360.","journal-title":"Redox Biol"},{"key":"6105_CR143","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.cmet.2011.03.010","volume":"13","author":"MP Murphy","year":"2011","unstructured":"Murphy MP, Holmgren A, Larsson NG, Halliwell B, Chang CJ, Kalyanaraman B, Rhee SG, Thornalley PJ, Partridge L, Gems D, et al. Unraveling the biological roles of reactive oxygen species. Cell Metab. 2011;13:361\u20136.","journal-title":"Cell Metab"},{"key":"6105_CR144","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202105442","volume":"9","author":"Z Yu","year":"2022","unstructured":"Yu Z, Fang X, Liu W, Sun R, Zhou J, Pu Y, Zhao M, Sun D, Xiang Z, Liu P, et al. Microglia regulate blood-brain barrier integrity via MiR-126a-5p\/MMP9 axis during inflammatory demyelination. Adv Sci (Weinh). 2022;9: e2105442.","journal-title":"Adv Sci (Weinh)"},{"key":"6105_CR145","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/s41582-019-0184-2","volume":"15","author":"AF Lloyd","year":"2019","unstructured":"Lloyd AF, Miron VE. The pro-remyelination properties of microglia in the central nervous system. Nat Rev Neurol. 2019;15:447\u201358.","journal-title":"Nat Rev Neurol"},{"key":"6105_CR146","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1038\/nn.3469","volume":"16","author":"VE Miron","year":"2013","unstructured":"Miron VE, Boyd A, Zhao JW, Yuen TJ, Ruckh JM, Shadrach JL, van Wijngaarden P, Wagers AJ, Williams A, Franklin RJM, Ffrench-Constant C. M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat Neurosci. 2013;16:1211\u20138.","journal-title":"Nat Neurosci"},{"key":"6105_CR147","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1167\/iovs.12-11207","volume":"54","author":"C Galindo-Romero","year":"2013","unstructured":"Galindo-Romero C, Valiente-Soriano FJ, Jim\u00e9nez-L\u00f3pez M, Garc\u00eda-Ayuso D, Villegas-P\u00e9rez MP, Vidal-Sanz M, Agudo-Barriuso M. Effect of brain-derived neurotrophic factor on mouse axotomized retinal ganglion cells and phagocytic microglia. Invest Ophthalmol Vis Sci. 2013;54:974\u201385.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"6105_CR148","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41593-020-00757-6","volume":"24","author":"SA Berghoff","year":"2021","unstructured":"Berghoff SA, Spieth L, Sun T, Hosang L, Schlaphoff L, Depp C, D\u00fcking T, Winchenbach J, Neuber J, Ewers D, et al. Microglia facilitate repair of demyelinated lesions via post-squalene sterol synthesis. Nat Neurosci. 2021;24:47\u201360.","journal-title":"Nat Neurosci"},{"key":"6105_CR149","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00401-023-02552-6","volume":"145","author":"A Geladaris","year":"2023","unstructured":"Geladaris A, H\u00e4usser-Kinzel S, Pretzsch R, Nissimov N, Lehmann-Horn K, H\u00e4usler D, Weber MS. IL-10-providing B cells govern pro-inflammatory activity of macrophages and microglia in CNS autoimmunity. Acta Neuropathol. 2023;145:461\u201377.","journal-title":"Acta Neuropathol"},{"key":"6105_CR150","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S1474-4422(20)30277-5","volume":"19","author":"RHB Benedict","year":"2020","unstructured":"Benedict RHB, Amato MP, DeLuca J, Geurts JJG. Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues. Lancet Neurol. 2020;19:860\u201371.","journal-title":"Lancet Neurol"},{"key":"6105_CR151","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41467-024-44917-9","volume":"15","author":"P Loginovic","year":"2024","unstructured":"Loginovic P, Wang F, Li J, Ferrat L, Mirshahi UL, Rao HS, Petzold A, Tyrrell J, Green HD, Weedon MN, et al. Applying a genetic risk score model to enhance prediction of future multiple sclerosis diagnosis at first presentation with optic neuritis. Nat Commun. 2024;15:1415.","journal-title":"Nat Commun"},{"key":"6105_CR152","first-page":"129","volume":"1","author":"P Connick","year":"2014","unstructured":"Connick P. Impairment of visual cognition in progressive multiple sclerosis. J Multiple Scleros. 2014;1:129.","journal-title":"J Multiple Scleros"},{"key":"6105_CR153","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ajo.2024.06.011","volume":"267","author":"MC Savastano","year":"2024","unstructured":"Savastano MC, Nociti V, Giannuzzi F, Cestrone V, Carl\u00e0 MM, Fossataro C, Biagini I, Rizzo C, Kilian R, Bisurgi M, et al. Optical coherence tomography advanced parameters in patients with multiple sclerosis: ophthalmological and neurological assessments. Am J Ophthalmol. 2024;267:41\u20139.","journal-title":"Am J Ophthalmol"},{"key":"6105_CR154","volume-title":"Optical coherence tomography (OCT) and angio-OCT imaging techniques in multiple sclerosis patients with or without optic neuritis","author":"B Mihaylova","year":"2022","unstructured":"Mihaylova B, Cherninkova S. Optical coherence tomography (OCT) and angio-OCT imaging techniques in multiple sclerosis patients with or without optic neuritis. IntechOpen; 2022."},{"key":"6105_CR155","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S1474-4422(14)70068-7","volume":"13","author":"PA Calabresi","year":"2014","unstructured":"Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A. Pegylated interferon \u03b2-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study. Lancet Neurol. 2014;13:657\u201365.","journal-title":"Lancet Neurol"},{"key":"6105_CR156","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376:221\u201334.","journal-title":"N Engl J Med"},{"key":"6105_CR157","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","volume":"87","author":"L Zhovtis Ryerson","year":"2016","unstructured":"Zhovtis Ryerson L, Frohman TC, Foley J, Kister I, Weinstock-Guttman B, Tornatore C, Pandey K, Donnelly S, Pawate S, Bomprezzi R, et al. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016;87:885\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"6105_CR158","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/vaccines9020099","volume":"9","author":"J Sellner","year":"2021","unstructured":"Sellner J, Rommer PS. Multiple sclerosis and SARS-CoV-2 vaccination: considerations for immune-depleting therapies. Vaccines (Basel). 2021;9:99.","journal-title":"Vaccines (Basel)"},{"key":"6105_CR159","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1056\/NEJM199312093292403","volume":"329","author":"RW Beck","year":"1993","unstructured":"Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW, Brown CH. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. N Engl J Med. 1993;329:1764\u20139.","journal-title":"N Engl J Med"},{"key":"6105_CR160","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/S0140-6736(98)03053-0","volume":"353","author":"L Kappos","year":"1999","unstructured":"Kappos L, Moeri D, Radue EW, Schoetzau A, Schweikert K, Barkhof F, Miller D, Guttmann CR, Weiner HL, Gasperini C, Filippi M. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet. 1999;353:964\u20139.","journal-title":"Lancet"},{"key":"6105_CR161","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1056\/NEJM200009283431301","volume":"343","author":"LD Jacobs","year":"2000","unstructured":"Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000;343:898\u2013904.","journal-title":"N Engl J Med"},{"key":"6105_CR162","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S0140-6736(09)61259-9","volume":"374","author":"G Comi","year":"2009","unstructured":"Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung HP, Hillert J, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1503\u201311.","journal-title":"Lancet"},{"key":"6105_CR163","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1177\/112067211002000123","volume":"20","author":"E Garcia-Martin","year":"2010","unstructured":"Garcia-Martin E, Pueyo V, Martin J, Almarcegui C, Ara JR, Dolz I, Honrubia FM, Fernandez FJ. Progressive changes in the retinal nerve fiber layer in patients with multiple sclerosis. Eur J Ophthalmol. 2010;20:167\u201373.","journal-title":"Eur J Ophthalmol"},{"key":"6105_CR164","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/WNO.0000000000000173","volume":"35","author":"S Chahin","year":"2015","unstructured":"Chahin S, Balcer LJ, Miller DM, Zhang A, Galetta SL. Vision in a phase 3 trial of natalizumab for multiple sclerosis: relation to disability and quality of life. J Neuroophthalmol. 2015;35:6\u201311.","journal-title":"J Neuroophthalmol"},{"key":"6105_CR165","doi-asserted-by":"publisher","first-page":"8077","DOI":"10.3390\/ijms23158077","volume":"23","author":"AG Vakrakou","year":"2022","unstructured":"Vakrakou AG, Alexaki A, Brinia ME, Anagnostouli M, Stefanis L, Stathopoulos P. The mTOR signaling pathway in multiple sclerosis; from animal models to human data. Int J Mol Sci. 2022;23:8077.","journal-title":"Int J Mol Sci"},{"key":"6105_CR166","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/19768354.2023.2234986","volume":"27","author":"H Jeong","year":"2023","unstructured":"Jeong H, Lee B, Han SJ, Sohn DH. Glucose metabolic reprogramming in autoimmune diseases. Anim Cells Syst (Seoul). 2023;27:149\u201358.","journal-title":"Anim Cells Syst (Seoul)"},{"key":"6105_CR167","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S1474-4422(22)00209-5","volume":"21","author":"A Svenningsson","year":"2022","unstructured":"Svenningsson A, Frisell T, Burman J, Salzer J, Fink K, Hallberg S, Hambraeus J, Axelsson M, Nimer FA, Sundstr\u00f6m P, et al. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Lancet Neurol. 2022;21:693\u2013703.","journal-title":"Lancet Neurol"},{"key":"6105_CR168","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1146\/annurev-pharmtox-010818-021358","volume":"59","author":"J Chun","year":"2019","unstructured":"Chun J, Kihara Y, Jonnalagadda D, Blaho VA. Fingolimod: lessons learned and new opportunities for treating multiple sclerosis and other disorders. Annu Rev Pharmacol Toxicol. 2019;59:149\u201370.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"6105_CR169","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/ana.26684","volume":"94","author":"R Holm Hansen","year":"2023","unstructured":"Holm Hansen R, von Essen MR, Mahler MR, Cobanovic S, Binko TS, Sellebjerg F. Cladribine effects on T and B cells and T cell reactivity in multiple sclerosis. Ann Neurol. 2023;94:518\u201330.","journal-title":"Ann Neurol"},{"key":"6105_CR170","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s40265-022-01672-9","volume":"82","author":"YN Lamb","year":"2022","unstructured":"Lamb YN. Ocrelizumab: a review in multiple sclerosis. Drugs. 2022;82:323\u201334.","journal-title":"Drugs"},{"key":"6105_CR171","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383:546\u201357.","journal-title":"N Engl J Med"},{"key":"6105_CR172","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s40265-023-01854-z","volume":"83","author":"A Lee","year":"2023","unstructured":"Lee A. Ublituximab: first approval. Drugs. 2023;83:455\u20139.","journal-title":"Drugs"},{"key":"6105_CR173","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1080\/14712598.2022.2143262","volume":"22","author":"SA Doggrell","year":"2022","unstructured":"Doggrell SA. The ULTIMATE trials: are there advantages of ublituximab over teriflunomide in relapsing multiple sclerosis? Expert Opin Biol Ther. 2022;22:1339\u201343.","journal-title":"Expert Opin Biol Ther"},{"key":"6105_CR174","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1007\/s13311-020-00950-2","volume":"17","author":"M Zhong","year":"2020","unstructured":"Zhong M, van der Walt A, Campagna MP, Stankovich J, Butzkueven H, Jokubaitis V. The pharmacogenetics of rituximab: potential implications for anti-CD20 therapies in multiple sclerosis. Neurotherapeutics. 2020;17:1768\u201384.","journal-title":"Neurotherapeutics"},{"key":"6105_CR175","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S1474-4422(16)00004-1","volume":"15","author":"R Raftopoulos","year":"2016","unstructured":"Raftopoulos R, Hickman SJ, Toosy A, Sharrack B, Mallik S, Paling D, Altmann DR, Yiannakas MC, Malladi P, Sheridan R, et al. Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15:259\u201369.","journal-title":"Lancet Neurol"},{"key":"6105_CR176","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1038\/nm1668","volume":"13","author":"MA Friese","year":"2007","unstructured":"Friese MA, Craner MJ, Etzensperger R, Vergo S, Wemmie JA, Welsh MJ, Vincent A, Fugger L. Acid-sensing ion channel-1 contributes to axonal degeneration in autoimmune inflammation of the central nervous system. Nat Med. 2007;13:1483\u20139.","journal-title":"Nat Med"},{"key":"6105_CR177","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1093\/brain\/aws325","volume":"136","author":"T Arun","year":"2013","unstructured":"Arun T, Tomassini V, Sbardella E, de Ruiter MB, Matthews L, Leite MI, Gelineau-Morel R, Cavey A, Vergo S, Craner M, et al. Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride. Brain. 2013;136:106\u201315.","journal-title":"Brain"},{"key":"6105_CR178","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/WNO.0000000000000697","volume":"39","author":"J Petrillo","year":"2019","unstructured":"Petrillo J, Balcer L, Galetta S, Chai Y, Xu L, Cadavid D. Initial impairment and recovery of vision-related functioning in participants with acute optic neuritis from the RENEW trial of opicinumab. J Neuroophthalmol. 2019;39:153\u201360.","journal-title":"J Neuroophthalmol"},{"key":"6105_CR179","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S1474-4422(16)30377-5","volume":"16","author":"D Cadavid","year":"2017","unstructured":"Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, Frederiksen J, Skeen M, Jaffe GJ, Butzkueven H. Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16:189\u201399.","journal-title":"Lancet Neurol"},{"key":"6105_CR180","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1016\/S0140-6736(17)32346-2","volume":"390","author":"AJ Green","year":"2017","unstructured":"Green AJ, Gelfand JM, Cree BA, Bevan C, Boscardin WJ, Mei F, Inman J, Arnow S, Devereux M, Abounasr A, et al. Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD): a randomised, controlled, double-blind, crossover trial. Lancet. 2017;390:2481\u20139.","journal-title":"Lancet"},{"key":"6105_CR181","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/nm.3618","volume":"20","author":"F Mei","year":"2014","unstructured":"Mei F, Fancy SPJ, Shen YA, Niu J, Zhao C, Presley B, Miao E, Lee S, Mayoral SR, Redmond SA, et al. Micropillar arrays as a high-throughput screening platform for therapeutics in multiple sclerosis. Nat Med. 2014;20:954\u201360.","journal-title":"Nat Med"},{"key":"6105_CR182","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1177\/13524585241234783","volume":"30","author":"X Montalban","year":"2024","unstructured":"Montalban X, Piasecka-Stryczynska K, Kuhle J, Benkert P, Arnold DL, Weber MS, Seitzinger A, Guehring H, Shaw J, Tomic D, et al. Efficacy and safety results after >3.5 years of treatment with the Bruton\u2019s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study. Mult Scler. 2024;30:558\u201370.","journal-title":"Mult Scler"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06105-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06105-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06105-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T16:45:36Z","timestamp":1737477936000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06105-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":182,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6105"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06105-1","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"15 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}